All articles tagged with #ascvd risk
Adding coronary artery calcium (CAC) scoring to PREVENT-ASCVD risk estimates helped reclassify adults into more accurate risk categories and guide statin decisions in a US cohort; CAC=0 was linked to lower observed ASCVD risk and CAC>0 to higher risk, especially when statin eligibility was uncertain, with CAC-enhanced risk stratification improving net reclassification across risk tiers.
A multicenter prospective trial shows a retinal-imaging AI (CLAiR AI) accurately estimates 10-year ASCVD risk and could help identify patients who may benefit from lipid-lowering therapy. Among 847 participants without ASCVD, about 26% had a 10-year risk ≥7.5% (the older threshold), while the 2026 ACC/AHA PREVENT guideline lowers the threshold to 5%, potentially expanding statin eligibility. The AI achieved 91.1% sensitivity, 86.2% specificity, and ~0.96 AUC, using a standard slit-lamp camera that requires no dilation or blood draw and could be used in primary care or optometry. A larger validation is needed, and future outputs should ideally estimate actual disease risk (e.g., coronary plaque, heart attacks) beyond risk scoring.